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ABSTRACT
Nitroimidazoles  are  radiosensitizers  and  hypoxia 
detecting  chemosensitizers.  Intially  nitroimidazoles 
were  single  dose  antibiotic  drugs.  Recently, 
nitroimidazole  derivatives  have  emerged  as 
multifunctional “drug-biomarker monitors” chemical 
compounds with importance in treatment of tumors, 
monitoring hypoxia and safer imaging contrast agents 
to monitor the therapeutic progress.  Additionally, the 
number of nitroimidazole derivatives is growing and 
identified  their  importance  as  multifunctional 
nanoparticles.  The nanoparticle synthesis scheme of 
nitroimidazole was proposed as nitroimidazole caged 
with metal oxide inside polymer coating and labeled 
with marker biomolecules. We report the step by step 
user-friendly  new  co-precipitation  schemes  of 
nitroimidazole  carrier  nanoparticles  with  their 
mechanisms  of  drug  controlled  release  behavior, 
metal  oxide  sensitivity  to  imaging  modalities  and 
polymer coating chemistry developed at our lab. The 
multifunctional  nitroimidazole  nanoparticles  were 
useful in detection and monitoring of hypoxia, cancer 
chemotherapy  and  soft  tissue  infections.  In 
conclusion,  nitroimidazoles  are  potential 
multifunctional  molecules  useful  in  chemotherapy, 
antiparasitic  and  monitoring  hypoxia  with  greater 
possibility  of  simultaneous  use  of  radiolabeled 
2’nitroimidazoles  as  radiosensitizers,  MRI-PET-US 
contrast imaging agents.
Key words: nitroimidazole, radiosensitizers, imaging 
agent, antiparasitic, MRI-PET
1 INTRODUCTION
2’nitroimidazole  compounds  and  analogs  are 
becoming  state  of  art  radiosensitizers  and 
chemosensitizers  in  cancer  prevention  and 
management.  Apart  from  their  newly  discovered 
antitumor  properties  2’  nitroimidazoles  had  been 
proven  antiparasitic  drugs.  However,  their  toxicity 
was remained a major  issue as they showed strong 
DNA breaking properties by direct DNA binding and 
coupling with DNA strands and it caused skepticism 
of nitroimidazole acceptability as safe choice of non-
cancer  therapeutic  value.  The  binding  of 
nitroimidazole  with  polymer  depends  on  its 
hydrophilic  bonds  over  its  molecules  as  shown  in 
Figure 1.
  
Figure 1: The structure of 2’nitroimidazole is shown 
with active hydrophilic groups to bind with 
polyethylene
2 SYNTHESIS OF NITROIMIDAZOLE 
POLYMER COMPLEXES
cytotoxicity of liver cells
nitroimidazole
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2.1  The  synthesis  of  nitroimidazole  polymer 
complexes
The coprecipitation methods were used in our center 
since  the  inception  of  innovative  development  at 
center  of  nanomagnetics  and  biotechnology  using 
Bang’s  manual  initially  and  over  years  the 
technology was modified for different nanoparticles 
for various purposes [1].  Mainly the coprecipitation 
method  includes  the  general  steps  of:  1.  A  batch 
process  to  develop  and  prepare  the  composite 
particles.  A  0.05%  w/w;  10  ml  solution  of 
polyethylene  wax  (number  average  MW  of  700 
g/mole  (Honeywell  Corp.)  using  decaline  or 
octamethylcyclotetrasiloxane  OMCTS  (Dow 
Chemical  Company) at  150°C;  2.  To this  solution, 
iron  oxide  powder  is  added  with  30%-50%  w/w 
polyethylene, and sonicated at 50% amplitude for 30 
seconds;  3.  Then,  10  ml  of  tetraglyme  ("TG") 
(obtained from Sigma-Aldrich) is added to the iron-
oxide polyethylene mixture at 150°C, and sonicated 
at 50% amplitude for about 30 seconds;  4.Next, the 
mixture  is  immediately  cooled to  about 0°C in ice 
water held at 0°C. Within three to four minutes, the 
polyethylene-iron-oxide mixture  is  transformed into 
an emulsion with microdroplets made of supercooled 
polyethylene wax solution and iron oxide dispersed 
in a continuous phase of nonsolvent; 5. The emulsion 
is warmed to room temperature 27°C for 45 minutes 
to  make  polyethylene  and  maghemite  particles 
suspended in the emulsion. This emulsion is cooled 
to  -10°C  for  half  an  hour  to  form  a  macrophase 
separated  system  made  of  thin  reddish-brown 
sandwiched  between  top  solvent  layer  and  non-
solvent bottom layer; 6. The reddish-brown layer of 
polyethylene/iron  oxide  particles  is  centrifuged  to 
isolate  the  particles  from  solvent  mixture.  This 
general strategy was used at our center over several 
years as described elsewhere [1].
2.2 Other synthesis methods of polymer 
nitroimidazole complexes
2.2.1 Different polymers used for nitroimidazole 
Chitosan hydrogel beads were prepared by the cross-
linking method followed by enteric coating [3]. A C-
P-A  film  consisting  of  a  chitosan  top  layer  and 
sodium  alginate  sublayer  was  synthesized  and 
separated  by  an  ornidazole(nitroimidazole)-
incorporated  poly(vinyl  alcohol)  layer  [4].   The 
xanthan gum, pectin, carrageenan, beta-cyclodextrin 
(CD) or methacrylic acid-g-guar (MAA-g-GG) gum 
were used to coat nitroimidazole to design complexes 
[6].  The  branched  poly(ethylene  glycol)  of  5,000, 
10,000 and 20,000 Daltons size were used for ester 
linkage between polymer and nitroimidazole to make 
complexes  [9].  The  calcium  pectinate  coating  of 
nitroimidazole offered as ideal drug carrier [10]. 
2.2.2  The  nitroimidazole  release  across  polymer 
cage
For  measurements  of  controlled  etanidazole  drug 
release,  triplicate polymer discs were  incubated for 
known  intervals  in  2  ml  0.1  phosphate-buffered 
saline,  pH  7.4,  37  degrees  C  [23].  The  method 
offered a cumulative percentage of the loaded drug 
that appeared in these serial supernatant fractions was 
plotted vs. time. 
     The percentage of the drug that was loaded into 
each polymer and that was released vs. time was fit 
to the power function of the form y = (a) x tb, where 
y  is  the  cumulative  released  agent,  a  and  b  are 
constants and t is time (days).
3 DISCUSSION
The polymer bound nitroimidazoles compounds such 
as  metronidazoles,  etanidazoles,  tinidazoles  have 
been found useful as hypoxia markers in tumors [5, 
18,  23].  Nitroimidazole  polymer  complexes  as 
hydrogels, beads used as colon targeted drug delivery 
systems  is  emerging  [1,3,6,11,13,14,15,17,22]. 
Different  polymers  such  as  polyethylene  glycol 
[9,20],  poly  vinyl  alcohol  [4,24], 
polymethylmethacrylate[16],polysaccharides[6,11]. 
Other  uses of nitroimidazole polymer complexes as 
delivery systems are reported in periodontal diseases 
[2, 21], amebiasis [6, 13, 22], helicobector pylori [7], 
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gentamycin  [16],  vaginitis  [8],  gastritis  [10,  12], 
sprays [19], liposomes [25].
The microbes have been reported as potential coating 
to  carry  and  transport  nitroimidazoles  encaged  in 
polymers.  Of  mention,  gentamycin,  helicobector 
pylori  and  amoeba  microbes  have  been  found  as 
potential  candidates  as  targeted  nitroimidazole 
delivery[7,  16,  22].  Other  options  of  liposomes  as 
nitroimidazole  delivery systems have been reported 
as minicapsular extrusion system [25]. 
The  technique  of    using  non-pathogenic  bacteria 
such  as  Salmonella  is  an  innovative  approach  in 
tumor  as  they replicate  and exceed  1000-fold their 
concentration  in  tumor.  Salmonella  typhimurium 
strains accumulate at tumor sites and serve as carriers 
for drug bound contrast agents. The bacterial delivery 
system may serve to transport with nitroimidazole or 
chemosensitive drugs to the tumor site.  Salmonella  
BR  509  (rod  shaped  with  1  micron  in  length) 
incubated with  drug-bound polymer complex may be  
developed  as  tumor  targeting  systems.   Our 
nitroimidazole  transport  experiments  suggested that 
small  size of Mn+  particles  were  diffused into the 
Entamoeba histolytica cell membrane [26]. The liver 
cells  (Kupffer  cells) engulfed the iron oxide bound 
nitroimidazole in cultures and suggested that iron can 
function  as  contrast  agent  for  imaging  such  as 
magnetic  resonance imaging.  The use of attenuated 
Salmonella  typhimurium  BRD509  in  targeting  of 
drug-coated  MNP-loaded  Salmonella  organisms  to 
tumor sites was reported in administration of the anti-
cancer  drug  as  it  would  significantly  reduce  the 
toxicity  associated  with  prolonged  treatment  with 
high  doses  of chemotherapeutic  drugs  [27].    The 
dextrans  dicarboxylic  acid  hemiester  conjugates 
serve  as  potent  prodrugs  for  nitroimidazole  drug 
release in liver.  The release kinetics was dependent 
on time [28].
CONCLUSION
The nitroimidazoles are potent radiosensitizers,  and 
are  well  accepted  antiparasitic  compounds.  Their 
slow release across  colon and tumor is a challenge 
due  to  their  cytotoxicity  caused  by  their  DNA 
binding properties.
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